Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 07, 2020 07:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Announces Oral Presentation of Updated Data from Combination Therapy Trial of PV-10® and Keytruda® for Checkpoint-Refractory Advanced Cutaneous Melanoma at Melanoma Bridge 2020

29% ORR (7% CR) and 57% DCR (RECIST 1.1)75% ORR in anti-PD-1-refractory patients56% DCR (11% CR) in patients refractory to anti-CTLA-4 and anti-PD-1 combination therapyPresentation delivered by...
May 07, 2018 08:00 ET | Source: Provectus Biopharmaceuticals Inc.

PROVECTUS BIOPHARMACEUTICALS COMPLETES ENROLLMENT OF PHASE 1B TRIAL OF PV-10 IN COMBINATION WITH KEYTRUDA® IN PATIENTS WITH METASTATIC MELANOMA

FOR IMMEDIATE RELEASE Data presentation planned for first half of 2019 KNOXVILLE, TN, May 07, 2018 (GLOBE NEWSWIRE) -- Provectus today announced the completion of enrollment of 24 patients...